AstraZeneca to use American AI platform for cancer trials

In a collaboration AstraZeneca will use an AI model from Israeli-American biotech Immunai to streamline its clinical trials in cancer.

CAR-T therapies give continued hope: “Almost half of the patients have become disease-free”

When the first CAR-T therapies appeared, hopes were raised for the effective treatment for critically ill cancer patients. After a somewhat sluggish start, abou...

Settlement of cancer allegations against blockbuster drug

French pharmaceutical company Sanofi has reached a principal agreement in the US on around 4,000 of the cases in which its now withdrawn blockbuster heartburn d...

Lucy Robertshaw: Did you know Stockholm wants to be in top 5 in the world for Life Sciences?

Karolinska Institutet Solna Campus has certainly become the next “Kendall Square”, writes Lucy Robertshaw in a column.

Setback for pharmaceutical companies in the Zantac case

A Delaware judge has ruled in favour of allowing expert witnesses to testify in a case involving the now-cancelled drug Zantac and its potential carcinogenicity.

Integrated solutions for liquid handling

Greater efficiency for manufacturers in laboratory automation and many other industries

BioArctic moves forward with its candidate for Parkinson’s

BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.

Lucy Robertshaw: Are we in the perfect storm?

“Is there a perfect storm on the horizon again as elective surgeries were cancelled due to patients being admitted with Covid-19? We now have a long backlog of ...

Tougher competition as the Novo Nordisk Foundation broadens its programme

Søren Nedergaard has worked with innovation at the Danish Government Offices and the University of Copenhagen. Today, he is COO of the Novo Nordisk Foundation, ...

The Swedish National Board of Health and Welfare rejects prioritising andrology as a speciality

Male infertility can be linked to a shorter lifespan and several severe diseases, but when couples who want children are examined, the focus is on the woman. Ex...

Delivering drugs with small devices

There are many challenges to overcome when delivering a drug orally. Getting the drug to survive the low pH of the ventricle and being released at the correct s...

The Oresund region aims at becoming Europe’s microbiome Mecca

The Medicon Valley Alliance’s ambition: Skåne and the Copenhagen region will become world leaders in microbiome research.

Sweden and Denmark – this is how they choose their strategies

Scandinavia’s two major powers in pharmaceutical research have developed strategies for growth in life science, and both countries aim to become world leaders.

From spin-off to phase II

”The people there will basically become your new colleagues” – Carina Schmidt, former CEO of Athera, about working with different contractors.

Hypothesis testing versus conspiracy theory

"How do you know what is a conspiracy theory and what is a reasonable, scientifically based conclusion?" In a column, Ingrid Lönnstedt reflects on this question.

Automated opening and closing of sample vials

From technical requirements to a suitable solution

Marie Gårdmark: New incentives for orphan products on its way

"Let’s hope that the learnings from development of new therapies for rare diseases will spill over to more common conditions, orphan products paving the wave fo...

CTC Clinical Trial Consultants AB

Toppnamn till Smartcellas styrelse

KI-professorn Anna Martling och Regina Fritsche-Danielson, vetenskaplig ledare för Astra Zenecas forskningsanläggning i Göteborg, tar bägge plats i biotech- och...

Japanese pharma to buy US drugmaker for $2.4 bln

Japanese Ono Pharmaceutical buys the American cancer drug developer Deciphera Pharmaceuticals in one of the largest acquisitions in the industry so far this year.

Swedish and Danish Life Science – are there still untapped synergies?

With the increasing developments in life sciences over the past decade and strong support for the sector’s strategic importance from both the Sweden and Danish ...

Novo Nordisk sues compounding pharmacies in the US

Novo Nordisk is suing compounding pharmacies in Florida, USA, because the company claims to have found impurities in the active ingredient in the obesity drug Wegovy.

Uppsala-based company wins important patent dispute – but the decision is subject to appeal

A US district court has ruled in favour of Orexo in a dispute over the patent protecting the Swedish company’s drug Zubsolv, developed for treating patients wit...

Life science trends 2025 – Part 1 obesity drugs

More obesity drugs are being launched this year following Novo Nordisk and Eli Lilly's previous successes with GLP-1 drugs. But the next big breakthrough in obe...